Introduction {#s1}
============

Acute respiratory distress syndrome (ARDS) is a life-threatening lung condition characterized by refractory hypoxemia and decreased lung compliance ([@B9]; [@B24]). In spite of advanced therapeutic techniques, ARDS is still associated with poor prognosis. Epidemiological data have revealed that hospital mortality is approximately 35--46%, depending on the severity of ARDS ([@B4]). Therefore, identification of an effective treatment method is of utmost importance for ARDS patients.

The primary reason for hypoxemia and hypercarbia in ARDS is an increased shunt fraction due to ventilation/perfusion mismatch ([@B29]). These gas exchange abnormalities lead to increased minute ventilation and patient-ventilator dyssynchrony. A previous study indicated that patients with greater numbers of dyssynchronies have poorer prognosis ([@B5]). Neuromuscular blocking agents (NMBA) have been recommended for ARDS patients with a PaO~2~/FiO~2~ ratio \<150 mmHg, especially for mechanically ventilated patients with ventilator dyssynchrony ([@B20]). A recent meta-analysis indicated that a 48 h NMBA infusion might reduce intensive care unit (ICU) mortality in patients with moderate-to-severe ARDS ([@B30]). In addition, NMBA has been associated with a lower risk of barotrauma, while it did not seem to increase the risk of ICU-acquired weakness ([@B22]; [@B1]). However, the benefit of NMBA was not confirmed by a recently published randomized controlled trial, the Reevaluation of Systemic Early Neuromuscular Blockade (ROSE) trial ([@B19]), leaving the use of NMBA in ARDS patients unclear and controversial. Accordingly, this updated meta-analysis includes the ROSE trial to further assess the effect of NMBA on mortality, and better understand its use and adverse outcomes in the literature published to date.

Materials and Methods {#s2}
=====================

Search Strategy {#s2_1}
---------------

PubMed, Web of Science, ClinicalTrials.gov, and the Cochrane Library were searched to find randomized controlled trials that evaluated the use of NMBA in ARDS patients from inception to July 2019. Keywords used to perform the search were "neuromuscular blockade" or "neuromuscular blocking agent" or "neuromuscular blocker" or "cisatracurium" and "acute respiratory distress syndrome" or "ARDS" or "acute lung injury". We also reviewed the potentially eligible studies from the references of the previous published meta-analysis. The language was limited to English.

Selection Criteria and Endpoints {#s2_2}
--------------------------------

The search results were independently scanned by two of the authors (WG and XL). Any disagreements were resolved by consensus with a third author (SW). Randomized controlled trials comparing infusion of NMBA vs. non-NMBA in ARDS patients were included. Exclusion criteria were as follows: ([@B24]) duplicate publications; ([@B9]) non-randomized controlled trials; and ([@B4]) lack of information on pre-defined endpoints. The endpoints included 28-day and ICU mortality, barotrauma, and ICU-acquired weakness.

Data Extraction and Quality Assessment {#s2_3}
--------------------------------------

The following data were extracted from all included studies: first author\'s name, publication year, definition of ARDS, patients\' characteristics, sample size, treatment protocol, and outcomes. Quality was assessed by the Cochrane Risk of Bias tool, including random sequence generation, allocation concealment, blinding of participants and personnel, blinding of outcome assessment, incomplete outcome data, and selective reporting ([@B14]).

Statistical Analysis {#s2_4}
--------------------

Study heterogeneity was assessed through Q statistics and I-squared. We regarded I-squared \<25%, 25-50%, and \>50% as low, moderate, and high heterogeneity, respectively. The effect of NMBA on outcomes in ARDS patients was shown as relative risk (RR) with 95% confidence interval (CI). The random-effect model was used if I-squared \>50%. In addition, publication bias was evaluated by funnel plots or Egger\'s linear regression test. All analyses were performed with STATA version 12.0 (Stata Corp., College Station, TX, USA). A *P* value \<0.05 was considered as a statistically significant difference.

Results {#s3}
=======

A flow diagram of the screening strategy for inclusion in the meta-analysis is displayed in [**Figure 1**](#f1){ref-type="fig"}. A total of 627 results were identified according to the search strategy: PubMed (*n* = 297), Web of Sciences (*n* = 329), and the Cochrane Library (*n* = 1). Among these, 195 were excluded because they were duplicates, and 402 were excluded because they did not meet the inclusion criteria after independently reviewing their titles and abstracts. The remaining 30 records were considered to be of relevance and the full papers were carefully screened. Four meta-analyses, 11 review articles, two case reports, four comments, two retrospective studies, and two studies in Chinese language were discarded. Finally, five eligible randomized controlled trials met the selection criteria ([@B23]; [@B14]; [@B1]; [@B12]; [@B19]). A total of 1,461 ARDS patients were included, where 724 were treated by NMBA. The detailed characteristics of these studies are listed in [**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}. ARDS was defined by a PaO~2~:FIO~2~ ratio \<150 mmHg in four studies ([@B11]; [@B23]; [@B12]; [@B19]) and in the remaining study by a PaO~2~:FIO~2~ ratio \<200 mmHg ([@B10]). All the intervention groups received 48 h cisatracurium infusion for myorelaxation. In three randomized controlled trials, the sample size was less than 100 patients ([@B11]; [@B10]; [@B12]). The risk of bias assessment is shown in [**Table 3**](#T3){ref-type="table"}. A double-blind method with a low risk of bias ([@B23]) was used in only one study.

![Flow chart of the study selection strategy.](fphar-10-01637-g001){#f1}

###### 

Study characteristics.

  Study    Number of centers   Definition of ARDS                                   Sample size   Location   Sedation strategy                             NMBA usage
  -------- ------------------- ---------------------------------------------------- ------------- ---------- --------------------------------------------- ----------------------------------------------------------------------------------
  [@B11]   4                   PaO~2~:FIO~2~ ratio \<150 mmHg and PEEP ≥5cmH~2~O    56            France     Midazolam and sufentanil                      A bolus of 50 mg cisatracurium, followed by 5 μg/(kg∙min) infusion for 48 h.
  [@B10]   3                   PaO~2~:FIO~2~ ratio \<200 mmHg and PEEP ≥5cmH~2~O    36            France     Midazolam and sufentanil                      A bolus of 0.2 mg/kg cisatracurium, followed by 5 μg/(kg∙min) infusion for 48 h.
  [@B23]   20                  PaO~2~:FIO~2~ ratio \< 150 mmHg and PEEP ≥5cmH~2~O   339           France     Midazolam, sufentanil, Ketamin and propofol   A bolus of 15 mg cisatracurium followed by 37.5 mg per hour for 48 hours.
  [@B12]   2                   PaO~2~:FIO~2~ ratio \<150 mmHg and PEEP ≥5cmH~2~O    24            France     Midazolam and sufentanil                      A bolus of 15 mg cisatracurium, followed 37.5 mg per hour for 48 hours.
  [@B19]   13                  PaO~2~:FIO~2~ ratio \<150 mmHg and PEEP ≥8cmH~2~O    1006          America    Not mandate                                   A bolus of 15 mg cisatracurium, followed 37.5 mg per hour for 48 hours.

NMBA, neuromuscular blocking agents; ARDS, acute respiratory distress syndrome; PEEP, positive end-expiratory pressure; ICU, intensive care unit.

###### 

Characteristics of NMBA and control group in included studies.

  Characteristics                            [@B11]        [@B10]        [@B23]        [@B12]        [@B19]                                                                            
  ------------------------------------------ ------------- ------------- ------------- ------------- --------------- -------------- ---------------- ---------------- ---------------- -------------
  Number of patients                         28            28            18            18            177             162            13               11               501              505
  Age                                        59.8 ± 17.5   61.5 ± 14.6   52.0 ± 16.0   61.0 ± 18.0   58.0 ± 16.0     58 ± 15.0      72 (63--79)      60 (52--75)      56.6 ± 14.7      55.1 ± 15.9
  Male sex                                   21 (75)       20 (71)       14 (78)       12 (67)       --              --             9 (69)           10 (91)          291 (58)         269 (53)
  Sedation scale                             Ramsay 6      Ramsay 6      Ramsay 6      Ramsay 6      Ramsay 6        Ramsay 6       Ramsay 6         Ramsay 6         Ramsay 6         Ramsay 2-3
  SAPS II                                    41.8 ± 10.4   45.4 ± 10.5   47.0 ± 15.0   49.0 ± 19.0   50.0 ± 16.0     47.0 ± 14.0    47 (37--54)      48 (42--62)      --               --
  PEEP, cmH2O                                11.1 ± 2.8    10.9 ± 2.4    13.2 ± 2.7    11.0 ± 2.7    9.2 ± 3.2       9.2 ± 3.5      11 (10-11.5)     10 (9--12)       12.6 ± 3.6       12.5 ± 3.6
  Plateau pressure, cmH~2~O                  27.1 ± 6.2    26.1 ± 4.0    27.5 ± 4.4    24.8 ± 5.7    25.0 ± 5.1      24.4 ± 4.7     23 (19--26)      21 (19--25)      25.5 ± 6.0       25.7 ± 6.1
  PaO~2~/FiO~2~                              130 ± 34      119 ± 31      105 ± 22      125 ± 20      106.0± 36.0     115.0± 41.0    158 (131--185)   150 (121--187)   98.7 ± 27.9      99.5 ± 27.9
  FiO~2~, %                                  70.2 ± 17.0   67.3 ± 15.8   80.0 ± 15.0   71.0 ± 19.0   79.0 ± 19.0     77.0 ± 22.0    60 (50--60)      50 (50--70)      80 ± 20          80 ± 20
  PaCO~2~, mmHg                              48.3 ± 9.0    47.4 ± 11.2   51.1 ± 9.9    47.2 ± 9.8    47.0 ± 11.0     47.0 ± 11.0    43(36-44)        43(37-52)        --               --
  VT, mL/kg                                  7.1 ± 1.1     7.4 ± 1.9     6.5 ± 0.7     7.0 ± 0.7     6.55 ± 1.12     6.48 ± 0.92    6.2 (5.9-6.8)    6.3 (6.0-6.9)    6.3 ± 0.9        6.3 ± 0.9
  Days free of ventilation at day 28         3.7 ± 7.2     1.7 ± 5.3     6.0 ± 8.6     5.4 ± 6.4     10.6 ± 9.7      8.5 ± 9.4      7 (0--20)        8 (0--18)        9.6 ± 10.4       9.9 ± 10.9
  ICU mortality                              13 (46.4)     20 (71.4)     5 (27.8)      10 (55.6)     52 (29.4)       63 (28.9)      5 (38)           3 (27)           --               --
  28 day mortality                           10 (35.7)     17 (60.7)     --            --            42 (23.7)       54 (33.3)      --               --               184 (36.7)       187 (37.0)
  Barotrauma                                 0             1 (3.6)       0             0             9 (5.1)         19 (11.7)      --               --               20 (4.0)         32 (6.3)
  ICU-acquired weakness, no./total no. (%)   0             0             1/18 (5.6)    1/18 (5.6)    40/112 (35.7)   28/89 (31.5)   --               --               107/226 (47.3)   89/228 (39)

NMBA, neuromuscular blocking agents; SAPS, simplified acute physiology score; PEEP, positive end-expiratory pressure; FiO~2,~ Fraction of inspired oxygen; VT, tidal volume; ICU, intensive care unit.

###### 

Risk of bias assessment.

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study    Random sequence generation   Allocation concealment   Blinding of participants and personnel   Blinding of outcome assessment   Incomplete outcome data   Selective reporting   Anything else, ideally prespecified
  -------- ---------------------------- ------------------------ ---------------------------------------- -------------------------------- ------------------------- --------------------- -------------------------------------
  [@B11]   Low risk of bias\            Low risk of bias\        High risk of bias\                       High risk of bias\               Low risk of bias\         Low risk of bias\     Low risk of bias\
           computer-generated           Centralized              Nurses aware of assignment               Analyst aware of assignment      outcome data complete     None                  None

  [@B10]   Low risk of bias\            Low risk of bias\        High risk of bias\                       High risk of bias\               Low risk of bias\         Low risk of bias\     Low risk of bias\
           computer-generated           Centralized              Nurses aware of assignment               Evaluators aware of assignment   outcome data complete     None                  None

  [@B23]   Low risk of bias\            Low risk of bias\        Low risk of bias\                        Low risk of bias\                Low risk of bias\         Low risk of bias\     Low risk of bias\
           computer-generated           Centralized              Blinding of all participants             Blinding of evaluators           outcome data complete     None                  None

  [@B12]   Low risk of bias\            unclear risk of bias     unclear risk of bias                     unclear risk of bias             Low risk of bias\         Low risk of bias\     Low risk of bias\
           computer-generated                                                                                                              outcome data complete     None                  None

  [@B19]   Low risk of bias\            Low risk of bias\        High risk of bias\                       High risk of bias\               Low risk of bias\         Low risk of bias\     Low risk of bias\
           computer-generated           Centralized              Participants aware of assignment         Evaluators aware of assignment   outcome data complete     None                  None
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The 28-day mortality was reported in three studies ([@B11]; [@B23]; [@B19]), including 1,401 patients (706 in the NMBA group vs. 695 in the control group). According to Egger\'s test, there were no significant differences for publication bias among these studies (*P* = 0.179), while the heterogeneity was statistically significant (I-squared = 62.8%, *P* = 0.068). The overall estimate based on the random-effect model showed that NMBA infusion did not reduce the 28-day mortality (33.4% vs. 37.1%, RR = 0.72, 95% CI 0.44 to 1.17, *P* = 0.180, [**Figure 2**](#f2){ref-type="fig"}). Subgroup analysis without the ROSE trial showed that the use of NMBA decreased the 28-day mortality (RR = 0.57, 95% CI 0.37 to 0.88, *P* = 0.011, I-squared = 0).

![Forest plot of RR and 95% CI for 28-day mortality. Three studies included 1,401 patients (706 in the NMBA group vs. 695 in the control group). The overall estimate based on the random-effect model showed that NMBA infusion did not reduce the 28-day mortality (33.4% vs. 37.1%, RR = 0.72, 95% CI 0.44 to 1.17, *P* = 0.180, I-squared = 62.8%).](fphar-10-01637-g002){#f2}

There were four randomized controlled trials (235/455 patients treated by NMBA) that discussed the ICU mortality ([@B11]; [@B10]; [@B23]; [@B12]). A funnel plot did not show distinct asymmetry ([**Figure 3**](#f3){ref-type="fig"}). The Egger\'s linear regression test did not suggest publication bias (*P* = 0.815). The incidence of ICU mortality was 31.9% in the NMBA group and 43.6% in the control group. The pooled estimate showed that NMBA infusion was associated with lower ICU mortality based on the fixed-effect model (RR = 0.60, 95% CI 0.41 to 0.88, *P* = 0.009, I-squared = 9.2%, [**Figure 4**](#f4){ref-type="fig"}).

![Funnel plot of studies discussing ICU mortality. The funnel plot did not show distinct asymmetry.](fphar-10-01637-g003){#f3}

![Forest plot of RR and 95% CI for ICU mortality. Four studies (235/455 patients treated by NMBA) that discussed the ICU mortality. The incidence of ICU mortality was 31.9% in the NMBA group and 43.6% in the control group. The pooled estimate showed that NMBA infusion was associated with lower ICU mortality based on the fixed-effect model (RR = 0.60, 95% CI 0.41 to 0.88, *P* = 0.009, I-squared = 9.2%).](fphar-10-01637-g004){#f4}

The incidences of barotrauma and ICU-acquired weakness were described in four randomized controlled trials with 1,437 patients (724 in NMBA group vs. 713 in control group) ([@B11]; [@B10]; [@B23]; [@B19]). The publication bias was not significantly different (*P* = 0.770). A low degree of nonsignificant heterogeneity was present (I-squared = 0). The meta-regression results with fixed-effects analysis suggested that the incidence of barotrauma was significantly lower in patients treated with NMBA (RR = 0.53, 95% CI 0.33 to 0.84, *P* = 0.007, [**Figure 5**](#f5){ref-type="fig"}). However, infusion of NMBA might increase the risk of ICU-acquired weakness based on the pooled estimate across the four studies (RR = 1.34, 95% CI 0.98 to 1.84, *P* = 0.066, I-squared = 0, [**Figure 6**](#f6){ref-type="fig"}).

![Forest plot of RR and 95% CI for the incidence of barotrauma. The incidence of barotrauma was described in four studies with 1,437 patients (724 in NMBA group vs. 713 in control group). The meta-regression results with fixed-effects analysis suggested that the incidence of barotrauma was significantly lower in patients treated with NMBA (RR = 0.53, 95% CI 0.33 to 0.84, *P* = 0.007, I-squared = 0).](fphar-10-01637-g005){#f5}

![Forest plot of RR and 95% CI for the incidence of ICU-acquired weakness. The incidence of ICU-acquired weakness was described in four studies with 1,437 patients (724 in NMBA group vs. 713 in control group). Infusion of NMBA might increase the risk of ICU-acquired weakness (RR = 1.34, 95% CI 0.98 to 1.84, *P* = 0.066, I-squared = 0).](fphar-10-01637-g006){#f6}

Discussion {#s4}
==========

Early NMBA treatment did not reduce the 28-day mortality in patients with moderate-to-severe ARDS. This result was mainly based on the study with the largest sample size ([@B19]). However, we found that the ICU mortality and incidence of barotrauma were lower in patients treated with NMBA. However, NMBA infusion may increase the risk of ICU-acquired weakness.

ARDS is an inflammatory disease that can lead to alveolar injury. The hallmark of ARDS is refractory hypoxia due to ventilation-perfusion mismatch ([@B29]). Mechanical ventilation is a conventional treatment for patients with ARDS ([@B8]). Patient-ventilator dyssynchrony, defined as a mismatch between the ventilatory needs of the patients and the amount of ventilation delivered, is a common problem present in about one-third of mechanically ventilated patients ([@B25]). In a period of low tidal volume ventilation in ARDS, the high metabolic rate and hypercarbia create significant ventilatory drive, leading to a greater risk of patient-ventilator dyssynchrony and a subsequent risk of volutrauma and barotrauma ([@B7]; [@B24]). NMBA has been suggested as a solution to this issue, because it can relax the skeletal muscles and achieve better patient-ventilatory synchrony and tidal volume control ([@B6]). Gainnier *et al*. were the first to evaluate the effects of NMBA infusion in ARDS patients. They conducted a randomized controlled trial of 56 ARDS patients with a PaO~2~/FIO~2~ ratio of \<150 mmHg at a positive end-expiratory pressure (PEEP) of \>5cm of water. The results revealed that NMBA usage could improve oxygenation and slightly reduce the ICU mortality (*P* = 0.057) ([@B11]). Furthermore, Forel and co-workers focused on another effect of NMBA in ARDS. They discovered that early NMBA administration decreases the proinflammatory response. However, no significant difference was found in ICU mortality due to the small sample size (*n* = 36) ([@B10]). A randomized controlled trial, the ARDS et Curarisation Systematique (ACURASYS) study, with a relatively large sample size (*n* = 339) was published in 2010 ([@B23]). This study provided evidence to support the use of NMBA in ARDS patients. The ACURASYS study demonstrated an improvement in 90-day survival without increasing the risk of ICU-acquired weakness in patients with severe ARDS. The meta-analysis of these three randomized controlled trials confirmed the benefits of NMBA use in ARDS patients ([@B22]; [@B1]). In contrast, the recently published ROSE trial did not demonstrate similar mortality reductions in what is the largest clinical study on this topic to date ([@B19]). Due to these inconsistencies, we conducted this updated meta-analysis to further evaluate the effect of NMBA in ARDS patients. Nonetheless, the impact of NMBA infusion on mortality mainly depended on the ROSE trial ([@B19]). In evaluating the ICU mortality without the ROSE trial, the effect of NMBA was favorable, whereas no significant difference was found when evaluating the 28-day mortality with this randomized controlled trial included. There are several reasons that might account for the inconformity between the ROSE trial and the ACURASYS study.

First, lung protective ventilation is an accepted and effective treatment for patients with ARDS, which decreases the short-term and long-term mortality owing to its reductions in inflammation and ventilator-induced lung injury (VILI) ([@B21]). The benefit of NMBA in the ACURASYS trial was only realized when the plateau pressure was incorporated into the multivariate analysis, suggesting that lung protective ventilation was perhaps less effectively applied in this trial compared to the ROSE trial. In addition, the ROSE trial enrolled patients much earlier than the ACURASYS trial. This raises the possibility that patients who experienced rapid improvement due to alveolar recruitment were included in the ROSE population, which potentially attenuated the NMBA signal.

Second, the mean PEEP in the ROSE trial was about 12 mmHg, which was higher than in the ACURASYS study ([@B23]). A previous study has shown that spontaneous breathing causes occult pendelluft in ARDS, which over-inflates the dependent lung near the diaphragm, and this could be mitigated by high PEEP ([@B33]; [@B35]; [@B18]). The higher mean level of PEEP in the ROSE trial could also have offered a greater degree of alveolar recruitment and attenuated the degree of hypoxemia and hypercapnia, which is one of the driving mechanisms of patient-ventilator dyssynchrony ([@B26]). Thus, one reason why the ROSE trial was negative, but the ACURASYS trial was positive, is that the low PEEP in the ACURASYS trial caused more VILI, which is why NMBA helped. However, in the ROSE trial, the high PEEP made NMBA unnecessary for reducing VILI.

Third, there was a substantially higher proportion of patients in the ACURASYS study who received prone positioning compared to less than 16% in the ROSE trial. In the ROSE trial, 20% of the patients were excluded for already using NMBA, whereas only 4% of patients in the ACURASYS study were excluded. These facts raise concern for a significant risk of selection bias, and attenuation of the treatment signal due to inclusion of a subset of patients with less physiologically severe lung injury. In addition, there was substantial cross-over between treatment groups in the ROSE trial, which may also lead to confounding. Finally, the patients in the ACURASYS trial were all deeply sedated, while only the patients in the intervention group were deeply sedated in the ROSE trial. Sedation is frequently prescribed in patients with ARDS, which facilitates tolerance of the intubation tube, reduces discomfort, and in some cases can improve patient-ventilator synchrony ([@B6]). Previous studies have indicated that early deep sedation can predispose a patient to double triggering and VILI, in addition to delirium, a longer time on mechanical ventilation or longer stay in the ICU, and an increased risk of ventilator-associated pneumonia ([@B3]; [@B28]). However, minimizing sedation had beneficial effects in critically ill patients, improving the ability to participate in early exercise and rehabilitation in patients with ARDS ([@B16]). Early mobilization was associated with a shortened length of stay in the ICU and improved physical function, potentially aiding in recovery from ARDS ([@B27]). The mismatch of sedation strategies between the two groups in the ROSE trial might contribute to the neutral effect of NMBA in ARDS. Therefore, we assumed that NMBA treatment could reduce the mortality according to our results.

We also found that the incidence of barotrauma was significantly lower in patients treated by NMBA (*P* = 0.007). Pulmonary barotrauma is a complication of mechanical ventilation, occurring in about 6.5% of ARDS patients and portending a poor outcome ([@B2]). The following aspects could account for the high incidence of barotrauma in ARDS patients. First, it is known that ARDS is a heterogeneous syndrome, in which atelectasis and edema are preferentially distributed to dependent lung regions, while independent lung regions are relatively well aerated ([@B31]). The positive pressure ventilation may theoretically lead to overdistention of relatively normal alveoli and ultimately barotrauma. Second, the permissive hypercapnia strategy commonly employed in the setting of a state of high ventilatory demand is also a contributing risk factor for barotrauma ([@B24]). Third, spontaneous breathing is involved in the barotrauma. In experimental studies, spontaneous breathing was associated with high transpulmonary pressure, which worsened injury in animals with severe lung injury ([@B32]; [@B34]). The vigorous spontaneous effort increased the risk of the dyssynchrony between the patients\' spontaneous effort and the ventilator, which can worsen lung injury ([@B36]). NMBA infusion could abolish spontaneous ventilatory activity and safeguard smooth implementation of lung protective ventilation, subsequently decreasing the occurrence of barotrauma.

Even so, the increased risk of ICU-acquired weakness needs attention. In our meta-analysis, we found that the incidence of ICU-acquired weakness was higher in patients who received NMBA treatment. This was in accordance with previous studies. Use of NMBA was an independent risk factor for ICU-acquired weakness, which subsequently increased the duration of mechanical ventilation and mortality ([@B15]). The potential mechanism was unclear. Recent data have shown that NMBA may not be associated with ICU-acquired weakness when used for less than 48 h ([@B17]). This conclusion remains inconsistent; thus, it needs to be further investigated. Although, some interventions could be considered to reduce the incidence of ICU-acquired weakness in patients receiving NMBA treatment, such as intensive insulin therapy, neuromuscular stimulation, and early exercise ([@B38]). However, the high risk of life-threatening hypoglycemia limits the application of intensive insulin therapy in clinical practice ([@B13]). Early mobilization may be an effective measure to reduce ICU-acquired weakness ([@B37]).

According to our analysis, we believe that the use of NMBA is still important for severe ARDS patients with refractory hypoxemia and patient-ventilator dyssynchrony, and at high risk of early barotrauma. However, it cannot be overused in patients with less severe ARDS, rapid improvement with initial ventilator strategies, and adequate lung protection and ventilator synchrony with light sedation, especially considering the signal towards an increased ICU-acquired weakness in NMBA patients and the signal suggesting an increased risk of cardiovascular events in the ROSE trial ([@B19]).

Limitations {#s5}
===========

There were some limitations in our study that should be pointed out. First, we did not evaluate the effect of other NMBA, except for cisatracurium, in ARDS, because all the studies included used cisatracurium infusion in the treatment group. Second, the dose-dependent effects of NMBA in ARDS were not fully understood due to the restrictions of the meta-analysis. Third, the inherent weaknesses of meta-analysis, such as publication bias and data combined from different protocols, might impact the results. Finally, the ICU mortality was not analyzed in recently published research ([@B1]). The beneficial effect of NMBA on ICU mortality might diminish with the inclusion of this study. However, there were some inconsistencies between experimental and control groups in the published study. The real effects of NMBA need to be further evaluated and confirmed by a study with a stricter design.

Conclusion {#s6}
==========

The results of the meta-analysis presented here support the use of NMBA in patients with moderate-to-severe ARDS. NMBA could reduce ICU mortality and the incidence of barotrauma. However, a continuous NMBA infusion needs to be used with caution, because it may increase the risk of ICU-acquired weakness. On account of the limitations in the ROSE trial, the effect of NMBA on mortality in ARDS patients needs to be clarified by further high-quality randomized controlled trials. Meanwhile, future studies should focus on the incidence of barotrauma, which may be a more appropriate surrogate outcome to examine in the study of the beneficial effects of NMBA, and this variable strongly favored this intervention. In addition, a greater awareness is needed of the increased risk of ICU-acquired weakness in patients undergoing NMBA treatment. Further research on ICU-acquired weakness is needed to better understand its pathophysiology, so that more effective interventions may be developed.
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